An amorphous solid dispersion (ASD) of Sorafenib (SOR) was used to develop an immediate release tablet with improved oral bioavailability. 

The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar^®. 

The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar^® tablets was performed by Medicilon.

Reference

Sichen Song, et al. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. Int J Pharm. 2021 Dec 15;610:121216. doi: 10.1016/j.ijpharm.2021.121216.